Table 2.
Metastatic response after two courses of TVD by site of metastatic disease at study entry
| Site of metastatic disease | Metastatic response after TVD |
||||||
|---|---|---|---|---|---|---|---|
| Eligible to HDT |
Not eligible to HDT |
||||||
| CR | PR ≤ 3 mIBG spots and negative bone marrow | PR > 3 mIBG spots and negative bone marrow | MR | SD | PD | ||
| Bone marrow only | 10 | 7 (70.0)a) | 0 | 0 | 0 | 3 (30.0) | 0 |
| Skeleton only | 25 | 5 (20.0)b) | 6 (24.0) | 4 (16.0) | 0 | 10 (40.0) | 0 |
| Combined bone marrow and skeleton | 27 | 5 (18.5)a),b) | 0 | 5 (18.5)a) | 16 (59.3) | 0 | 1 (3.7) |
| Liver | 1 | 0 | 0 | 0 | 0 | 1 (100) | 0 |
| Total | 63 | 17 (27.0) | 6 (9.5) | 9 (14.3) | 16 (25.4) | 14 (22.2) | 1 (1.6) |
Values are presented as number (%). Eligibility to HDT: p=0.012 (Fisher exact test). TVD, topotecan-vincristine-doxorubicin; HDT, high dose therapy; CR, complete response; mIBG, metaiodobenzylguanidine; PR, partial response; MR, mixed response; SD, stable disease; PD, progressive disease.
a)
BM cleared,
b)
Skeleton cleared.